Posted in | Nanomedicine

NanoViricides’ President Honored as ‘Researcher of the Year’

Published on April 1, 2014 at 8:53 AM

NanoViricides, Inc. (the “Company”) announced today that Anil R. Diwan, Ph.D., President, Chairman, and co-Founder of the Company was recognized as the “2014 Researcher of the Year” by BusinessNewHaven, a business journal, and New Haven Magazine, publications that serve the state of Connecticut.

The article was published in the February, 2014 issue of BusinessNewHaven, and is reproduced on the Company’s website with permission (www.nanoviricides.com/index.html#bnh-recognition). BusinessNewHaven recognizes “Healthcare Heroes” in the state of Connecticut every year. The heroes are chosen from all walks of life in various categories. The magazine seeks to recognize individuals particularly for their persistence, perseverance, novel approaches, and potential for impact on society. The magazines together have a combined circulation of over 40,000 in Connecticut.

“We recognized Dr. Diwan as the Researcher of the Year because we were impressed by his hard work, the ups and downs that he has faced over his long career in making NanoViricides, Inc. happen, and the fact that he did not quit in the face of adversity,” said Mitchell Young, Publisher of Second Wind Media Ltd., of which BusinessNewHaven Magazine is a part. “He was selected from several other nominations, because he represents the essence that we seek in a hero.”

“We at NanoViricides congratulate Anil for this recognition,” said Dr. Eugene Seymour, MD, MPH, CEO of the Company. “We all know the hard work and the brilliant technologies that he has brought forth.”

“I am very pleased with this recognition,” said Dr. Diwan. “There is still a long way ahead and I am committed to bringing our revolutionary technologies to benefit patients.”

About NanoViricides:

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Source: http://www.nanoviricides.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit